Drug Profile
Research programme: drug discovery - Infinity Pharmaceuticals/Mitsubishi Pharma Corporation
Latest Information Update: 16 Mar 2009
Price :
$50
*
At a glance
- Originator Infinity Pharmaceuticals; Mitsubishi Pharma Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 16 Mar 2009 NTTC-Infinity Pharmaceuticasl AR 2008
- 31 Dec 2008 Discontinued - Preclinical for Undefined indication in Japan (unspecified route)
- 31 Dec 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)